Conference Proceeding

Nonselective phosphodiesterase inhibition protects against chemotherapy induced peripheral neuropathy in mice and potentiates its apoptotic activity in colorectal adenocarcinoma

Mr. P.S.S Saikiran ,
Department of Pharmacology, JSS College of Pharmacy, Tamilnadu, India

Oxaliplatin (OXA) is a third-generation platinum based anticancer agent. OXA is widely used in treatment of advanced colorectal cancer.

Mr. Pindiprolu Satya Sesha Saikiran obtained his Bachelors in Pharmacy from Andhra University, Visakhapatnam and his masters from JSS University, Mysuru India. Presently he is working as a research scholar in department of pharmacology, college of pharmacy, JSS University, Ooty India.

Oxaliplatin (OXA) is a third-generation platinum based anticancer agent. OXA is widely used in treatment of advanced colorectal cancer. However, the major limitation of OXA based chemotherapy is peripheral neuropathy which is characterized by severe pain in hands and foot. Peripheral neuropathy also further leads to sensory disturbances and is one of the major reasons for cessation of treatment and hence responsible for decreased efficacy of chemotherapy and increased incidence of tumor relapse. Currently there are no approved medications for prevention of oxaliplatin induced peripheral neuropathy (OIPN). In the present study the protective propensity of Pentoxifylline (PTX), a non selective phospho diesterase against OIPN was studied. OXA (1mg/kg body wt) was administered twice weekly to mice, to induce peripheral neuropathy. The PTX was administered daily at doses of 15mg/kg and 30 mg/kg. The total duration of the study is 4 weeks. OIPN leads to alterations in nerve conduction velocity, oxidative stress and increased the levels of inflammatory markers. Whereas, PTX treatment showed dose dependent prevention of electrophysiological, behavioral and Biography chemical alterations associated with OIPN.

Published: 11 May 2017